The Role of Personal Identity in Psychotic Symptoms: a Study With the Repertory Grid Technique

January 25, 2019 updated by: Helena García Mieres, University of Barcelona

Personal Identity, Cognitive Factors and Psychotic Symptoms in Schizophrenia and Related Disorders: A Cross-sectional Study With the Repertory Grid Technique

Personal identity is being recently recognized as a core element for mental health disorders, with relevant clinical implications. However, scarcity of data exists on its role in schizophrenia and related disorders. The repertory grid (RGT), a technique derived from personal construct theory, has been used in different clinical and non-clinical contexts for the study of the construction perception of self and others, to appreciate aspects of interpersonal construing such as polarization and differentiation (unidimensional thinking) or self-construction.and Our study aims to explore the potential influence of the structure of personal identity and of other relevant cognitive factors (social cognition, metacognition, neurocognition) in positive and negative symptoms in people suffering schizophrenia and related disorders.

Study Overview

Status

Completed

Detailed Description

Over recent years, the importance of the sense of self and personal identity in psychopathology and its treatment has been highlighted. Several studies inspired in the Personal Construct Psychology framework have found a variety of identity characteristics in clinical conditions such as depression or eating disorders, but the evidence in schizophrenia and other psychotic related disorders is scarce.

In addition, current psychological models of positive and negative symptoms highlight the influence of neurocognition, social cognition and self-concepts in the development and maintenance of psychotic experiences. Despite the recognized need of person-centered approaches to understand psychopathology processes in psychosis, psychological models for explaining psychotic symptoms have not explored sufficiently the role of this kind of person-centered measures.

Aim

1. To examine the influence of the structure of personal identity and other relevant cognitive factors in positive and negative symptoms

Hypotheses

  1. Positive symptoms will be influenced by dichotomous thinking style and construction of self as measured with the RGT.
  2. Negative symptoms will be affected by the richness of the construct system as measured with the RGT.

Study Type

Observational

Enrollment (Actual)

85

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Barcelona
      • Sant Boi De Llobregat, Barcelona, Spain
        • Parc Sanitary Sant Joan de Déu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients recruited from the community, suffering schizophrenia and related disorder

Description

Inclusion Criteria:

  • diagnosis of schizophrenia, psychotic disorder not otherwise specified, delusional disorder, schizoaffective disorder, brief psychotic disorder, or schizophreniform disorder
  • age between 18 and 60 years.
  • patients from outpatient mental health units

Exclusion Criteria:

  • traumatic brain injury, dementia, or intellectual disability (pre-morbid IQ <70)
  • current substance dependence

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-ideal discrepancy, RGT
Time Frame: 2 hours
Self-esteem. Possible range: 0-0,60. Higher values represent a worse outcome
2 hours
Self-others discrepancy, RGT
Time Frame: 2 hours
Perceived social isolation. Possible range: 0-0,60. Higher values represent a worse outcome
2 hours
Interpersonal construct differentiation, RGT
Time Frame: 2 hours
Percentage of Variance Accounted for the First Factor. Possible range: 0-100. Higher values represent a worse outcome
2 hours
Polarization, RGT
Time Frame: 2 hours
Dichotomous thinking style in the interpersonal context. Possible range: 0-100. Higher values represent a worse outcome
2 hours
Number of elicited constructs, RGT
Time Frame: 2 hours
Quantity of constructs that the person is able to express to describe self and others. Possible range: 10-50. Higher values represent a better outcome
2 hours
Psychotic symptoms (PANSS, Kay et al. 1987; Peralta & Cuesta, 1994).
Time Frame: 40 minutes
Positive and negative symptoms of psychosis. Range: 7-112. Higher values represent a worse outcome.
40 minutes
Metacognition: BCIS (Beck et al. 2004; Gutiérrez-Zotes et al. 2012); Garety et al, 1991; Dudley et al, 1997)
Time Frame: 15 minutes
Cognitive insight. Range: 0-45. Higher values represent a better outcome
15 minutes
Theory of mind: the Hinting Task (Corcoran et al., 1995; Gil-Sanz et al., 2012)
Time Frame: 5 minutes
Possible range: 0-12. Higher values represent a better outcome
5 minutes
General intellectual functioning (WAIS)
Time Frame: 20 minutes
vocabulary subscale. Range: 70-140. Higher values represent a better outcome
20 minutes
Executive functioning: WSCT (Bergs et al., 1948)
Time Frame: 15 minutes
Wisconsin Card Sorting Test. Categories completed and perseverative errors. Higher values represent a better outcome
15 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sociodemographical data
Time Frame: 10 minutes
Gender, chronicity, antipsychotic dosage, diagnosis, age, marital status, education level, employment situation
10 minutes
Depressive symptoms
Time Frame: 10 minutes
Beck Depression Inventory (Beck et al. 1996; Sanz, Perdigón & Vázquez, 2003). Range_ 0-63. High values represent a worse outcome.
10 minutes
General functioning
Time Frame: 5 minutes
Global Assessment of Functioning (Endicot et al., 1976). Range: 0-100. Higher values represent a better outcome.
5 minutes
Self-esteem
Time Frame: 5 minutes
Rosenberg self-esteem scale (Martín Albó et al., 2007). Range: 0-40. Higher values represent a better outcome
5 minutes
Social functioning
Time Frame: 20 minutes
Social Functioning Scale (Birchwood et al., 1990; Torres & Olivares, 2000). Range: Range: 45-195
20 minutes
Psychological distress
Time Frame: 10 minutes
CORE-OM (Evans et al., 2002; Trujillo et al., 2016). Range: 0-4. Higher values represent a worse outcome
10 minutes
Jumping to Conclusions
Time Frame: 15 minutes
The beads task (Garety et al., 1991; Dudley et al, 1997). Dichotomous: yes/no. A "yes" represents a worse outcome
15 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Helena García-Mieres, MsC, Universitat de Barcelona & Parc Sanitari Sant Joan de Déu
  • Study Director: Susana Ochoa, PhD, Parc Sanitari Sant Joan de Déu
  • Study Director: Guillem Feixas, PhD, University of Barcelona

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2016

Primary Completion (Actual)

November 1, 2018

Study Completion (Actual)

November 1, 2018

Study Registration Dates

First Submitted

January 22, 2019

First Submitted That Met QC Criteria

January 25, 2019

First Posted (Actual)

January 29, 2019

Study Record Updates

Last Update Posted (Actual)

January 29, 2019

Last Update Submitted That Met QC Criteria

January 25, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychotic Disorders

3
Subscribe